Prostate-specific antigen levels as a predictor of lethal prostate cancer

Journal of the National Cancer Institute

Volumn 99, Issue 7, 2007, Pages 526-532

  Fall, Katja ^a   Garmo, Hans ^b   Andrén, Ove ^c   Bill Axelson, Anna ^d   Adolfsson, Jan ^e   Adami, Hans Olov ^a   Johansson, Jan Erik ^c   Holmberg, Lars ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCANDINAVIA; STATISTICAL MODEL; BLOOD; CANCER STAGING; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; REGRESSION ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; AGED; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SCANDINAVIA; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 34247630061     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk110     Document Type: Article

References (22)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
2. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
3. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-7.
4. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005;174:2191-6.
5. Vollmer RT, Egawa S, Kuwao S, Baba S. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: A study of 94 Japanese men. Cancer 2002;94:1692-8.
6. Holmberg L, Bill-Akelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
7. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
8. Sobin L, Wittekind C. TNM classification of malignant tumours. 6th ed. New York (NY): Wiley-Liss; 2002.
9. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging 1974. J Urol 2002;167(Pt 2):953-8; discussion 959.
10. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
11. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323-8.
12. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-40.
13. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York (NY): John Wiley; 2002.
14. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;496-509.
15. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56: 337-44.
16. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
17. Piironen T, Pettersson K, Suonpaa M, Stenman UH, Oesterling JE, Lovgren T, et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology 1996;48(Suppl)81-7.
18. Bruun L, Becker C, Hugosson J, Lilja H, Christensson A. Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate 2005; 65:216-21.
19. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997;24:283-91.
20. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.
21. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293: 2095-101.
22. Klotz LH, Choo R, Morton G, Danjoux C. Expectant management with selective delayed intervention for favorable-risk prostate cancer. Can J Urol 2002;9 Suppl 1:2-7.